Magrolimab + Azacitidine Versus Azacitidine + Placebo in Untreated Participants With Myelodysplastic Syndrome (MDS)
Stopped early · Phase 3 · Has a placebo group
Conditions studied: Myelodysplastic Syndromes
In brief
The primary objective of this study is to evaluate the efficacy of magrolimab in combination with azacitidine compared to that of azacitidine plus placebo in previously untreated participants with intermediate/high/very high risk myelodysplastic syndrome (MDS) by Revised International Prognostic Scoring System (IPSS-R) as measured by complete remission (CR) and overall survival (OS).
Key facts
- Study ID
- NCT04313881
- Run by
- Gilead Sciences
- People needed
- 539
- Starts
- 2020-09-09
- Expected to finish
- 2023-09-13
- Last updated by the study team
- 2024-06-27
Who can join
Age: 18 and older. Sex: any. Healthy volunteers: not accepted.
Where it is running
- University of Arkansas for Medical Sciences IRB — Little Rock, Arkansas, United States
- City of Hope — Duarte, California, United States
- UC San Diego Moores Cancer Center — La Jolla, California, United States
- UCLA Ronald Reagan Medical Center — Los Angeles, California, United States
- UC Irvine Health — Orange, California, United States
- Stanford Cancer Institute — Palo Alto, California, United States
- University of California, Davis Comprehensive Cancer Center — Sacramento, California, United States
- University of Miami Hospital and Clinics / Sylvester Comprehensive Cancer Center — Miami, Florida, United States
- Moffitt Cancer Center — Tampa, Florida, United States
- Winship Cancer Institute — Atlanta, Georgia, United States
- Northwestern Memorial Hospital — Chicago, Illinois, United States
- The University of Chicago Medical Center — Chicago, Illinois, United States
- University of Kansas Clinical Research Center — Fairway, Kansas, United States
- Tulane Medical Center — New Orleans, Louisiana, United States
- University of Maryland, Greenebaum Comprehensive Cancer Center — Baltimore, Maryland, United States
- Johns Hopkins Medicine - The Sidney Kimmel Comprehensive Cancer Center — Baltimore, Maryland, United States
- Massachusetts General Hospital — Boston, Massachusetts, United States
- Beth Israel Deaconess Medical Center — Boston, Massachusetts, United States
- Dana Farber Cancer Institute (DFCI) — Boston, Massachusetts, United States
- University of Michigan Medical School — Ann Arbor, Michigan, United States
- University of Minnesota Medical Center, Fairview — Minneapolis, Minnesota, United States
- Mid America Division, Inc. — Kansas City, Missouri, United States
- Washington University School of Medicine - Siteman Cancer Center — St Louis, Missouri, United States
- Roswell Park Cancer Institute — Buffalo, New York, United States
- University of Alabama Birmingham — Birmingham, Alabama, United States
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.